Updates to Contour ProtegeAI 4.0 reportedly include enhanced algorithms for radiation oncology segmentation and molecular radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated version of Contour ProtegeAI® 4.0 (MIM Software), a platform that provides automated deep learning segmentation for organs at risk (OARs).
Contour ProtegeAI 4.0 offers improved algorithms for radiation oncology as well as improvements for molecular radiotherapy, according to MIM Software.
“Over the past several months, the MIM Software team has worked hard to focus this new version on improving our contouring performance,” noted Jay Obman, a product manager at MIM Software, Inc. “The initial testing has shown a good improvement in our overall contour quality, and I’m excited for our users to reap the benefits of those improvements as well as some new contours we’ve added.”
The company adds that the software facilitates standardized, efficient workflows and provides automated preparation for physician target volume (PTV) contouring. Contour ProtegeAI 4.0 also integrates with Eclipse™, RayStation®, Monaco® and Pinnacle, according to MIM Software.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.